We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen’s First-in-Class Cholesterol Drug Edges Closer to Approval in Europe
Amgen’s First-in-Class Cholesterol Drug Edges Closer to Approval in Europe
California-based Amgen may soon be the first to get a new class of cholesterol-lowering biologics onto the European market, following a positive opinion from the European Medicines Agency on Friday.